|
|
|
|
|
|
|
3. Formation of a central point where coordination of the supervision of pharmacovigilance can take place; reporting will continue through Member States; |
|
|
|
|
|
|
|
|
4. Coordination of verification of compliance with Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP); inspections will still take place through the Member States; |
|
|
|
|
|
|
|
|
5. Provision of technical and scientific support to cooperation between the Community, Member States, international organizations (such as IFPMA, WHO, etc.), and third countries; |
|
|
|
|
|
|
|
|
6. Recording of the status of marketing authorizations; |
|
|
|
|
|
|
|
|
7. Provision of technical assistance for maintenance of a public database on medicinal products; |
|
|
|
|
|
|
|
|
8. Provision of information to health care professionals and the public about medicinal products that have been evaluated by the Agency; and |
|
|
|
|
|
|
|
|
9. Advising of companies on the nature and extent of the various tests and trials necessary to develop new products. |
|
|
|
|
|
|
|
|
The Executive Director is responsible to the Management Board. This Board consists of two representatives from each Member State, two representatives from the European Commission, and two representatives appointed by the |
|
|
|
|
|
